Article Text

other Versions

Download PDFPDF
EMA suspends licence for ulipristal acetate for uterine fibroids

Abstract

Every month, DTB scans sources of information on treatments, disease management and other healthcare topics for key items to bring to our readers’ attention and help them keep up to date. To do this, we produce succinct, contextualised summaries of the information concerned.

  • Health Care Quality, Access, and Evaluation
  • Primary Health Care
View Full Text

Statistics from Altmetric.com

Footnotes

  • Overview of: Medicines and Healthcare products Regulatory Agency. Esmya (ulipristal acetate): suspension of the licence due to risk of serious liver injury. Drug Safety Update 2020;13(8):1.

  • Contributors DTB Team.

  • Provenance and peer review Commissioned; internally peer reviewed.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.